News | November 07, 2024
JB Pharma posts Q2 FY25 PAT 16% higher at Rs. 175 Cr
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
This product is categorized as antacids, antiflatulents and anti-Ulcerants
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
We now rank 3rd in pharmaceutical production by volume and 14th by value
Stable profits, low leverage to keep credit profiles comfortable
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
Subscribe To Our Newsletter & Stay Updated
